Alnylam Pharmaceuticals (ALNY) Cash from Operations Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 75.53% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 332.04% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 4.87% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -28.96% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 42.76% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 151.70% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 178.99% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 56.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 151.70% |
| Mar 31, 2026 | 158.60% |
| Dec 31, 2025 | 272.78% |
| Sep 30, 2025 | 703.14% |
| Jun 30, 2025 | 4.55% |
| Mar 31, 2025 | -47.59% |
| Dec 31, 2024 | -217.71% |
| Sep 30, 2024 | -87.84% |
| Jun 30, 2024 | 310.49% |
| Mar 31, 2024 | 51.03% |
| Dec 31, 2023 | 77.42% |
| Sep 30, 2023 | 411.76% |
| Jun 30, 2023 | 51.97% |
| Mar 31, 2023 | 2.76% |
| Dec 31, 2022 | 12.10% |
| Sep 30, 2022 | 13.99% |
| Jun 30, 2022 | -0.79% |
| Mar 31, 2022 | 27.36% |
| Dec 31, 2021 | -21.92% |
| Sep 30, 2021 | -21.49% |